Mayo Clinic Hospital
- Type
- Teaching hospital
- Where
- Phoenix, AZ
- Medicare CCN
- 030103
- Received
- $14,445,260 in 1,171 records, 2020 ($1,091,825 general, $13,353,434 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 234 | $1,091,825 |
| 2020 | Research payment | 937 | $13,353,434 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 937 | $13,353,434 |
| Grant | 53 | $602,762 |
| Space rental or facility fees (teaching hospital only) | 101 | $271,724 |
| Education | 9 | $84,844 |
| Gift | 63 | $63,335 |
| Consulting Fee | 3 | $47,659 |
| Charitable Contribution | 5 | $21,500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AngioDynamics, Inc. | $60,000 | Education | In-kind items and services | Nanoknife Device, Oncology Surgery | 2020 | |
| 2020-12-31 | Monteris Medical Corporation | $50,000 | Grant | In-kind items and services | Neuroblate Device, Neuroblate | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $17,811 | Research payment | Cash or cash equivalent | Mayo2020MRIPR926928015Panda | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $12,375 | Research payment | Cash or cash equivalent | Mayo2019MRiPR928Panda | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $10,262 | Research payment | Cash or cash equivalent | Mayo2018MRIPR887IPR926Panda | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $8,817 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $7,247 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $6,188 | Research payment | Cash or cash equivalent | Mayo2019MRIPR932Panda | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $5,167 | Research payment | Cash or cash equivalent | Mayo2018MRIPR10231029928838Panda | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $3,094 | Research payment | Cash or cash equivalent | Mayo2019MRIPR1061Panda | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,875 | Research payment | Cash or cash equivalent | Mayo2019MRIPR990Panda | 2020 | |
| 2020-12-31 | Stryker Corporation | $1,220 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,125 | Research payment | Cash or cash equivalent | Mayo2019MRIPR1058ZhouArizona | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $366 | Research payment | Cash or cash equivalent | Mayo2020MRIPR990Panda | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $355 | Research payment | Cash or cash equivalent | Mayo2020MRIPR925Zhou | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $205 | Research payment | In-kind items and services | A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durval | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $180 | Research payment | In-kind items and services | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2020 | |
| 2020-12-30 | Merck Sharp & Dohme LLC | $820 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-12-24 | Regeneron Pharmaceuticals, Inc. | $1,281 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $162 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $162 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-23 | Blueprint Medicines Corporation | $23,839 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2020 | |
| 2020-12-23 | GE HEALTHCARE | $10,000 | Consulting Fee | Cash or cash equivalent | Device, ULTRASOUND | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $2,161 | Research payment | Cash or cash equivalent | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | 2020 | |
| 2020-12-23 | ABBVIE INC. | $1,578 | Research payment | Cash or cash equivalent | M14-011 | 2020 | |
| 2020-12-23 | SEAGEN INC. | $1,350 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-12-23 | Intercept Pharmaceuticals, Inc. | $1,116 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-23 | Intercept Pharmaceuticals, Inc. | $279 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-22 | GE HEALTHCARE | $72,438 | Research payment | Cash or cash equivalent | DATSCAN IMAGING IN AGING WITH NEURODEGERATIVE DISEASES | 2020 | |
| 2020-12-22 | Nevro Corp. | $6,750 | Research payment | Cash or cash equivalent | Senza Spinal Cord Stimulation System Device, Spinal Cord Stimulator | Post Market Observational Study | 2020 |
| 2020-12-22 | Roche Products Limited | $4,519 | Research payment | Cash or cash equivalent | VENCLEXTA Biological, BioOncology | SAFETY AND EFFICACY OF VENETOCLAX FULVESTRANT IN ER POSITIVE METASTATIC BREAST CANCER | 2020 |
| 2020-12-22 | Clovis Oncology, Inc. | $2,884 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-12-22 | Clovis Oncology, Inc. | $2,297 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-12-22 | Incyte Corporation | $474 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-22 | Clovis Oncology, Inc. | $380 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-12-22 | Clovis Oncology, Inc. | $190 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-12-21 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-12-21 | Janssen Research & Development, LLC | $23,100 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Pr | 2020 | |
| 2020-12-21 | Cook Research Incorporated | $3,056 | Research payment | Cash or cash equivalent | (13-003) A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Fema | 2020 | |
| 2020-12-21 | Cook Research Incorporated | $1,179 | Research payment | Cash or cash equivalent | (13-003) A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Fema | 2020 | |
| 2020-12-18 | Incyte Corporation | $57,194 | Research payment | Cash or cash equivalent | Ruxolitinib Cream in the Treatment of Necrobiosis Lipoidica | 2020 | |
| 2020-12-18 | Janssen Research & Development, LLC | $15,293 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2020 | |
| 2020-12-18 | Incyte Corporation | $15,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-18 | EMD Serono, Inc. | $2,090 | Research payment | Cash or cash equivalent | M7824 TRAP | A Phase II, Multicenter, Open Label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants with | 2020 |
| 2020-12-18 | EMD Serono, Inc. | $2,066 | Research payment | Cash or cash equivalent | M7824 TRAP | A Phase II, Multicenter, Open Label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants with | 2020 |
| 2020-12-18 | Roche Products Limited | $240 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PPMS | 2020 |
| 2020-12-17 | Exelixis Inc. | $26,447 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-17 | Agios Pharmaceuticals, Inc. | $948 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-12-16 | GE HEALTHCARE | $3,750 | Research payment | Cash or cash equivalent | ASSESSMENT OF WALL THICKNESS IN HYPERTROPHIC CARDIOMYOPATHY: A PROSPECTIVE MULTIMODALITY COMPARISON BETWEEN CARDIAC MRI | 2020 | |
| 2020-12-16 | Azurity Pharmaceuticals, Inc. | $2,675 | Research payment | In-kind items and services | FIRVANQ Drug, Infectious disease | Vancomycin for Primary Sclerosing Cholangitis | 2020 |
| 2020-12-16 | Abbott Laboratories | $275 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | Allergan, Inc. | $1,248 | Research payment | Cash or cash equivalent | Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steato | 2020 | |
| 2020-12-14 | Ipsen Bioscience Inc. | $7,750 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan Nal-IRI-Containing Regimens Versus Nab-Paclitaxel Plu | 2020 |
| 2020-12-09 | SEAGEN INC. | $24,350 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-12-09 | SEAGEN INC. | $12,440 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-12-09 | SEAGEN INC. | $11,385 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2020 |
| 2020-12-09 | Genentech, Inc. | $9,470 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-12-09 | Agios Pharmaceuticals, Inc. | $7,746 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinica | 2020 |
| 2020-12-09 | PFIZER INC. | $7,200 | Research payment | Cash or cash equivalent | A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 | 2020 | |
| 2020-12-09 | Deciphera Pharmaceuticals Inc. | $5,500 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-09 | Alexion Pharmaceuticals, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Soliris Drug, Immunology | 2020 | |
| 2020-12-09 | Deciphera Pharmaceuticals Inc. | $1,250 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Incyte Corporation | $85 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-08 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-08 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-08 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-07 | Blueprint Medicines Corporation | $20,432 | Research payment | Cash or cash equivalent | BLU-667-1101 | 2020 | |
| 2020-12-07 | Blueprint Medicines Corporation | $10,700 | Research payment | Cash or cash equivalent | BLU-667-1101 | 2020 | |
| 2020-12-07 | Boston Scientific Corporation | $5,500 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DOUBLE J | 2020 |
| 2020-12-07 | Boston Scientific Corporation | $4,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DOUBLE J | 2020 |
| 2020-12-07 | Janssen Research & Development, LLC | $1,250 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-04 | GENZYME CORPORATION | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LIBTAYO Biological, Oncology | 2020 | |
| 2020-12-03 | Blueprint Medicines Corporation | $6,750 | Research payment | Cash or cash equivalent | BLU-667-1101 | 2020 | |
| 2020-12-03 | Olympus Corporation of the Americas | $5,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-03 | Genentech, Inc. | $2,889 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-12-03 | Agios Pharmaceuticals, Inc. | $2,202 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-12-03 | Agios Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-12-03 | Agios Pharmaceuticals, Inc. | $450 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-12-03 | Agios Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-12-02 | Deciphera Pharmaceuticals Inc. | $106,666 | Research payment | In-kind items and services | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-01 | EMD Serono, Inc. | $6,418 | Research payment | Cash or cash equivalent | M7824 TRAP | A Phase II, Multicenter, Open Label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants with | 2020 |
| 2020-12-01 | Clovis Oncology, Inc. | $6,416 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-12-01 | EMD Serono, Inc. | $1,958 | Research payment | Cash or cash equivalent | M7824 TRAP | A Phase II, Multicenter, Open Label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants with | 2020 |
| 2020-12-01 | Clovis Oncology, Inc. | $132 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-11-30 | Janssen Research & Development, LLC | $2,450 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-11-30 | Merck Sharp & Dohme LLC | $574 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-26 | Regeneron Pharmaceuticals, Inc. | $34,139 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-11-24 | Intercept Pharmaceuticals, Inc. | $4,794 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-11-24 | Astellas Pharma Global Development | $2,139 | Research payment | Cash or cash equivalent | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A NON-INTERVENTIONAL REGISTRY STUDY OF SYSTEMIC ANTIFUNGAL THERAPY IN ADULT SUBJECTS WITH INVASIVE MUCORMYCOSIS OR INVAS | 2020 |
| 2020-11-23 | Janssen Research & Development, LLC | $3,482 | Research payment | Cash or cash equivalent | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | 2020 | |
| 2020-11-20 | Janssen Research & Development, LLC | $12,970 | Research payment | Cash or cash equivalent | A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subject | 2020 | |
| 2020-11-20 | Ipsen Biopharmaceuticals, Inc | $5,000 | Education | Cash or cash equivalent | ONIVYDE Drug, Oncology | 2020 | |
| 2020-11-19 | Cook Incorporated | $2,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-18 | Incyte Corporation | $11,950 | Research payment | Cash or cash equivalent | Phase IIa Study of Addition of Itacitinib with Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melp | 2020 | |
| 2020-11-18 | Incyte Corporation | $11,101 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-18 | Exelixis Inc. | $10,000 | Grant | Cash or cash equivalent | Cabometyx Drug, Oncology | 2020 | |
| 2020-11-18 | PFIZER INC. | $6,726 | Research payment | Cash or cash equivalent | A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 | 2020 | |
| 2020-11-18 | Blueprint Medicines Corporation | $1,584 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2020 | |
| 2020-11-18 | ABBVIE INC. | $1,500 | Grant | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | 2020 | |
| 2020-11-17 | KARL STORZ Endoscopy-America | $117,500 | Research payment | Cash or cash equivalent | NEPHROSCOPE Device, UROLOGY | Standard vs Mini-PCNL for the Treatment of Stone Disease | 2020 |
| 2020-11-17 | TAIHO ONCOLOGY, INC. | $10,000 | Grant | Cash or cash equivalent | Lonsurf Drug, Oncology | 2020 | |
| 2020-11-17 | CSL Behring | $2,500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-17 | CSL Behring | $1,250 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-17 | CSL Behring | $950 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-16 | Covidien LP | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-13 | ABBVIE INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-11-13 | Merck Sharp & Dohme LLC | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-11-13 | ABBVIE INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-11-12 | Clovis Oncology, Inc. | $6,500 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-11-12 | Novocure Inc. | $4,865 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2020 |
| 2020-11-12 | Novocure Inc. | $3,493 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2020 |
| 2020-11-12 | Novocure Inc. | $2,817 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2020 |
| 2020-11-12 | Novocure Inc. | $2,655 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2020 |
| 2020-11-12 | Novocure Inc. | $1,722 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2020 |
| 2020-11-12 | Biogen, Inc. | $1,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-12 | Clovis Oncology, Inc. | $1,250 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-11-12 | Incyte Corporation | $1,250 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-11-12 | CSL Behring | $1,124 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-12 | Novocure Inc. | $355 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2020 |
| 2020-11-12 | JAZZ PHARMACEUTICALS INC. | $279 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY/ONCOLOGY | JZP 395-201: PROSPECTIVE, MULTICENTER, OPEN-LABEL, SINGLE ARM, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DEFI | 2020 |
| 2020-11-11 | SEAGEN INC. | $23,100 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase 1b Dose Escalation Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy for HER | 2020 |
| 2020-11-11 | PUMA BIOTECHNOLOGY, INC. | $1,593 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | THIS IS AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, MULTINATIONAL, PHASE 2 STUDY | 2020 |
| 2020-11-10 | E.R. Squibb & Sons, L.L.C. | $19,386 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph I Hematology CA210-003 | 2020 |
| 2020-11-10 | Hoffmann-La Roche Limited | $12,445 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE | 2020 |
| 2020-11-10 | CSL Behring | $5,500 | Research payment | Cash or cash equivalent | Privigen Biological, Immunology | A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro1 | 2020 |
| 2020-11-10 | CSL Behring | $4,548 | Research payment | Cash or cash equivalent | Haegarda Biological, Immunology | A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri | 2020 |
| 2020-11-10 | Genentech USA, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AVASTIN Biological, BioOncology | 2020 | |
| 2020-11-10 | CSL Behring | $900 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-10 | Merck Sharp & Dohme LLC | $191 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Reapplix Inc. | $4,000 | Research payment | Cash or cash equivalent | 3C PATCH Device, wound healing | 20-000917 Reapplix 3C Patch System for the Treatment of Diabetic Foot Ulcers A Medicare Claims Study | 2020 |
| 2020-11-09 | Janssen Research & Development, LLC | $1,797 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2020 | |
| 2020-11-09 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-06 | Integra LifeSciences Corporation | $2,500 | Grant | Cash or cash equivalent | CUSA CLARITY Device, NEURO CRITICAL CARE | 2020 | |
| 2020-11-06 | Roche Products Limited | $1,200 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PPMS | 2020 |
| 2020-11-06 | Roche Products Limited | $1,000 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PPMS | 2020 |
| 2020-11-05 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-11-05 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-11-05 | Agios Pharmaceuticals, Inc. | $1,292 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-11-05 | CSL Behring | $950 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-11-04 | Genentech, Inc. | $7,750 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-11-03 | United Therapeutics Corporation | $4,000 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2020 |
| 2020-11-03 | Incyte Corporation | $3,029 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-03 | United Therapeutics Corporation | $2,400 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2020 |
| 2020-11-03 | E.R. Squibb & Sons, L.L.C. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-11-03 | E.R. Squibb & Sons, L.L.C. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-11-02 | Janssen Research & Development, LLC | $18,380 | Research payment | Cash or cash equivalent | A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subject | 2020 | |
| 2020-10-29 | Exelixis Inc. | $22,260 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-29 | Nevro Corp. | $17,320 | Research payment | Cash or cash equivalent | Senza Spinal Cord Stimulation System Device, Spinal Cord Stimulator | Post Market Observational Study | 2020 |
| 2020-10-29 | Regeneron Pharmaceuticals, Inc. | $4,526 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF REGN3500 MONOTHERAPY | 2020 | |
| 2020-10-29 | Foundation Medicine, Inc. | $1,500 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-10-27 | Exelixis Inc. | $20,464 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-27 | Exelixis Inc. | $15,479 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-27 | AstraZeneca Pharmaceuticals LP | $14,714 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2020 |
| 2020-10-27 | Exelixis Inc. | $14,643 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-27 | AstraZeneca Pharmaceuticals LP | $6,750 | Research payment | Cash or cash equivalent | A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durval | 2020 | |
| 2020-10-27 | Exelixis Inc. | $1,170 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-27 | Exelixis Inc. | $1,170 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-27 | Exelixis Inc. | $650 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-27 | Exelixis Inc. | $478 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-27 | Exelixis Inc. | $195 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-27 | CSL Behring | $152 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-10-27 | Exelixis Inc. | $71 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-10-26 | E.R. Squibb & Sons, L.L.C. | $5,950 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-10-26 | Allergan, Inc. | $2,496 | Research payment | Cash or cash equivalent | Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steato | 2020 | |
| 2020-10-22 | Clovis Oncology, Inc. | $8,684 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-10-22 | Boehringer Ingelheim International GmbH | $3,148 | Research payment | Cash or cash equivalent | BAML-16-001-S2/BI 836858 with 5-Aza | 2020 | |
| 2020-10-22 | EMD Serono, Inc. | $2,300 | Research payment | Cash or cash equivalent | M7824 TRAP | A Phase II, Multicenter, Open Label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants with | 2020 |
| 2020-10-22 | EMD Serono, Inc. | $2,066 | Research payment | Cash or cash equivalent | M7824 TRAP | A Phase II, Multicenter, Open Label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants with | 2020 |
| 2020-10-22 | EMD Serono, Inc. | $1,958 | Research payment | Cash or cash equivalent | M7824 TRAP | A Phase II, Multicenter, Open Label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants with | 2020 |
| 2020-10-22 | Olympus America Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Colonoscopes Device, Medical | 2020 | |
| 2020-10-22 | Roche Products Limited | $1,313 | Research payment | Cash or cash equivalent | VENCLEXTA Biological, BioOncology | SAFETY AND EFFICACY OF VENETOCLAX FULVESTRANT IN ER POSITIVE METASTATIC BREAST CANCER | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $390 | Research payment | Cash or cash equivalent | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | 2020 | |
| 2020-10-19 | JAZZ PHARMACEUTICALS INC. | $72,797 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY/ONCOLOGY | JZP 395-201: PROSPECTIVE, MULTICENTER, OPEN-LABEL, SINGLE ARM, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DEFI | 2020 |
| 2020-10-19 | Actelion Pharmaceuticals, Ltd | $8,909 | Research payment | Cash or cash equivalent | Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventri | 2020 | |
| 2020-10-19 | Incyte Corporation | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PEMAZYRE Drug, Hepatology (Liver, Pancreatic, Gall Bladder) | 2020 | |
| 2020-10-19 | LEICA MICROSYSTEMS INC. | $198 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-15 | Roche Products Limited | $18,889 | Research payment | Cash or cash equivalent | VENCLEXTA Biological, BioOncology | SAFETY AND EFFICACY OF VENETOCLAX FULVESTRANT IN ER POSITIVE METASTATIC BREAST CANCER | 2020 |
| 2020-10-15 | Clovis Oncology, Inc. | $6,500 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-10-15 | Alexion Pharmaceuticals, Inc. | $1,921 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients | 2020 |
| 2020-10-15 | Clovis Oncology, Inc. | $1,710 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $1,536 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-10-15 | Clovis Oncology, Inc. | $1,250 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-10-15 | Clovis Oncology, Inc. | $132 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-10-14 | SEAGEN INC. | $8,508 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2020 |
| 2020-10-14 | Blueprint Medicines Corporation | $6,511 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2020 | |
| 2020-10-14 | Blueprint Medicines Corporation | $4,282 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2020 | |
| 2020-10-14 | Genentech USA, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-10-14 | La Jolla Pharmaceutical Company | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | GIAPREZA Drug, EMERGENT HYPOTENSION | 2020 | |
| 2020-10-13 | Clovis Oncology, Inc. | $5,227 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-10-13 | Alexion Pharmaceuticals, Inc. | $1,250 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients | 2020 |
| 2020-10-13 | Merck Sharp & Dohme LLC | $383 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-10-13 | Stryker Corporation | $57 | Gift | In-kind items and services | SURG - SYSTEM 8 Device, SURGICAL | 2020 | |
| 2020-10-12 | Janssen Research & Development, LLC | $28,972 | Research payment | Cash or cash equivalent | A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subject | 2020 | |
| 2020-10-10 | KYOWA KIRIN, INC. | $1,500 | Education | Cash or cash equivalent | SANCUSO Drug, ANTIEMETIC - 5HT3 INHIBITOR | 2020 | |
| 2020-10-08 | Boehringer Ingelheim International GmbH | $12,592 | Research payment | Cash or cash equivalent | BAML-16-001-S2/BI 836858 with 5-Aza | 2020 | |
| 2020-10-08 | Agios Pharmaceuticals, Inc. | $6,126 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-10-08 | Agios Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
The latest 200 records of 1,171.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Phoenix, AZ, county Maricopa County, AZ, state Arizona; placed by its city name.
| Measure | Place (city or town) Phoenix, AZ | County Maricopa County, AZ | State Arizona |
|---|---|---|---|
| Population B01003 | 1,642,323 | 4,559,748 | 7,378,838 |
| Population, 2020 census P1 | 1,608,139 | 4,420,568 | 7,151,502 |
| Median age B01002 | 34.9 | 37.6 | 39.0 |
| Under 18 B01001 | 23.6% | 22.5% | 21.6% |
| 65 and over B01001 | 12.2% | 16.3% | 18.9% |
| Households B11001 | 610,442 | 1,730,696 | 2,856,081 |
| Foreign born B05002 | 19.0% | 14.5% | 13.0% |
| Median household income B19013 | $81,332 | $89,300 | $79,964 |
| Median family income B19113 | $94,886 | $105,249 | $95,980 |
| Per capita income B19301 | $41,981 | $46,183 | $42,503 |
| Poverty rate B17001 | 13.7% | 11.0% | 12.5% |
| Unemployment rate B23025 | 5.0% | 4.5% | 5.1% |
| Civilian labor force B23025 | 887,179 | 2,373,071 | 3,598,840 |
| Mean commute (minutes) B08013 | 25.6 | 26.0 | 25.4 |
| Bachelor's degree or higher B15003 | 33.6% | 36.7% | 33.3% |
| Housing units B25001 | 653,065 | 1,884,334 | 3,192,839 |
| Owner-occupied B25003 | 57.3% | 65.2% | 67.4% |
| Renters B25003 | 42.7% | 34.8% | 32.6% |
| Median home value B25077 | $420,700 | $452,800 | $394,500 |
| Median gross rent B25064 | $1,582 | $1,708 | $1,543 |
| White, not Hispanic B03002 | 40.6% | 52.5% | 52.6% |
| Black B03002 | 7.4% | 5.4% | 4.4% |
| Hispanic or Latino B03002 | 42.0% | 31.2% | 31.4% |
| Asian B03002 | 4.0% | 4.5% | 3.5% |
| American Indian and Alaska Native B03002 | 1.4% | 1.3% | 3.2% |
Economy now FRED unemployment 4.9% in Sep 2026 (4.4% a year earlier); per capita personal income $68,373 in 2025, up 31% in five years (+5.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Phoenix, AZ.
Comments